tetano
Editor, Senior Moderator
Antiviral Res
. 2024 May 11:105905.
doi: 10.1016/j.antiviral.2024.105905. Online ahead of print. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
Jingbo Huang[SUP] 1 [/SUP], Weiqi Wang[SUP] 2 [/SUP], Hailun Li[SUP] 3 [/SUP], Yujie Bai[SUP] 3 [/SUP], Yumeng Song[SUP] 3 [/SUP], Cuicui Jiao[SUP] 3 [/SUP], Hongli Jin[SUP] 4 [/SUP], Pei Huang[SUP] 3 [/SUP], Haili Zhang[SUP] 3 [/SUP], Xianzhu Xia[SUP] 2 [/SUP], Feihu Yan[SUP] 2 [/SUP], Yuanyuan Li[SUP] 3 [/SUP], Hualei Wang[SUP] 5 [/SUP]
Affiliations
The rapid emergence of Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) variants, coupled with severe immune evasion and imprinting, has jeopardized the vaccine efficacy, necessitating urgent development of broad protective vaccines. Here, we propose a strategy employing recombinant rabies viruses (RABV) to create a universal SARS-CoV-2 vaccine expressing heterologous tandem receptor-binding domain (RBD) trimer from the SARS-CoV-2 Prototype, Delta, and Omicron strains (SRV-PDO). The results of mouse immunization indicated that SRV-PDO effectively induced cellular and humoral immune responses, and demonstrated higher immunogenicity and broader SARS-CoV-2 neutralization compared to the recombinant RABVs that only expressed RBD monomers. Moreover, SRV-PDO exhibited full protection against SARS-CoV-2 in the challenge assay. This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.
Keywords: Immunogens; RBD; Recombinant rabies virus; SARS-CoV-2; Tandem RBD-heterotrimer; Universal Vaccine.
. 2024 May 11:105905.
doi: 10.1016/j.antiviral.2024.105905. Online ahead of print. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2
Jingbo Huang[SUP] 1 [/SUP], Weiqi Wang[SUP] 2 [/SUP], Hailun Li[SUP] 3 [/SUP], Yujie Bai[SUP] 3 [/SUP], Yumeng Song[SUP] 3 [/SUP], Cuicui Jiao[SUP] 3 [/SUP], Hongli Jin[SUP] 4 [/SUP], Pei Huang[SUP] 3 [/SUP], Haili Zhang[SUP] 3 [/SUP], Xianzhu Xia[SUP] 2 [/SUP], Feihu Yan[SUP] 2 [/SUP], Yuanyuan Li[SUP] 3 [/SUP], Hualei Wang[SUP] 5 [/SUP]
Affiliations
- PMID: 38740191
- DOI: 10.1016/j.antiviral.2024.105905
The rapid emergence of Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) variants, coupled with severe immune evasion and imprinting, has jeopardized the vaccine efficacy, necessitating urgent development of broad protective vaccines. Here, we propose a strategy employing recombinant rabies viruses (RABV) to create a universal SARS-CoV-2 vaccine expressing heterologous tandem receptor-binding domain (RBD) trimer from the SARS-CoV-2 Prototype, Delta, and Omicron strains (SRV-PDO). The results of mouse immunization indicated that SRV-PDO effectively induced cellular and humoral immune responses, and demonstrated higher immunogenicity and broader SARS-CoV-2 neutralization compared to the recombinant RABVs that only expressed RBD monomers. Moreover, SRV-PDO exhibited full protection against SARS-CoV-2 in the challenge assay. This study demonstrates that recombinant RABV expressing tandem RBD-heterotrimer as a multivalent immunogen could elicit a broad-spectrum immune response and potent protection against SARS-CoV-2, making it a promising candidate for future human or veterinary vaccines and offering a novel perspective in other vaccine design.
Keywords: Immunogens; RBD; Recombinant rabies virus; SARS-CoV-2; Tandem RBD-heterotrimer; Universal Vaccine.